Ignite Creation Date:
2025-12-24 @ 10:50 PM
Ignite Modification Date:
2025-12-25 @ 8:20 PM
Study NCT ID:
NCT05534269
Status:
COMPLETED
Last Update Posted:
2025-08-08
First Post:
2022-08-23
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Stress Urinary Incontinence Study to Assess Safety and Efficacy of Muvon's Muscle Precursor Cell Therapy
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014550', 'term': 'Urinary Incontinence, Stress'}], 'ancestors': [{'id': 'D014549', 'term': 'Urinary Incontinence'}, {'id': 'D014555', 'term': 'Urination Disorders'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D059411', 'term': 'Lower Urinary Tract Symptoms'}, {'id': 'D020924', 'term': 'Urological Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT'], 'maskingDescription': 'Neither patient nor sponsor will know which patient gets which dose'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Low dose and High dose evaluation'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 30}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-10-17', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-07', 'completionDateStruct': {'date': '2025-07-14', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-08-04', 'studyFirstSubmitDate': '2022-08-23', 'studyFirstSubmitQcDate': '2022-09-06', 'lastUpdatePostDateStruct': {'date': '2025-08-08', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-09-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-07-14', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Change in total leakage episodes', 'timeFrame': '8-9 months', 'description': 'Response rate at 6 months, defined as percentage of patients with at least 50% change in number of stress leaks'}, {'measure': 'Questionnaire ICIQ-UI SF (International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form )', 'timeFrame': '8-9 months', 'description': 'Change in score from baseline to 6 months. Containing 1 scale ranging from 0 (not at all) to 10 (serious) measuring the impairment caused by urine leakage in everyday life.'}, {'measure': 'Questionnaire ICIQLUTSqol (International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms quality of Life)', 'timeFrame': '8-9 months', 'description': 'Change in score from baseline to 6 months. This questionnaire contains 21 questions to measure the impact of urinary incontinence on quality of life with particular reference to social effects. Each question is accompanied by a scale to capture the subjective restriction concerning the respective topic. These scales range from 0 (not at all) to 10 (very much).'}, {'measure': 'Questionnaire VAS (Visual analogue scale)', 'timeFrame': '8-9 months', 'description': 'Change score for degree of suffering, quality of life overall and subjective health status from baseline to 6 months. Scales ranging from 0 to 10. For Quality of life and health status from 0 "very bad" to 10 "very well". The degree of suffering from 0 (low) to 10 (high).'}, {'measure': 'Urethral pressure profile', 'timeFrame': '8-9 months', 'description': 'It measures the changes in the bladder pressure (in cm/H2O) required to urinate and the flow rate (in ml/s) a given pressure generates between baseline and 6 months after injection.'}, {'measure': 'Urodynamic cystometric test', 'timeFrame': '8-9 months', 'description': 'It measures the change of how much urine (in mL) the bladder can hold, between baseline and 6 months after injection.'}, {'measure': 'Urodynamic cystometric test', 'timeFrame': '8-9 months', 'description': 'It measures the change how much pressure builds up inside the bladder (in cm/H2O) as it stores urine, between baseline and 6 months after injection.'}, {'measure': 'Urodynamic cystometric test', 'timeFrame': '8-9 months', 'description': 'It measures the change how full the bladder is (in mL) when the urge to urinate occurs, between baseline and 6 months after injection.'}, {'measure': 'Urodynamic leak point pressure measurement', 'timeFrame': '8-9 months', 'description': 'It measures the changes of pressure (in cm/H2O) at the point of leakage between baseline and 6 months after injection.'}, {'measure': '% of subjects with successful injection', 'timeFrame': '1 day', 'description': 'at day of implantation'}, {'measure': 'MRI evaluation: Increase of sphincter diameter and (S)AEs', 'timeFrame': '8-9 months', 'description': 'MRI examinations of the rhabdomyosphincter at baseline visit and after ca. 6 months after the MPC injection at the end of the study. This means approximately 8-9 months after the baseline visit.\n\nDuring the MRI we will measure the increase in sphincter diameter as well as looking for potential aberrant tissue formation and necrosis. The outcome will be reportet via MRI-pictures and data measurement provided by a Radiologist via the internal hospital system.'}, {'measure': 'PGI-I Questionnaire', 'timeFrame': '8-9 months', 'description': 'Response to Patient Global Impression of Improvement Questionnaire, ca. 6 months after MPC injection at end of study visit.'}, {'measure': 'Device deficiency, ADEs and SADEs related to the Injection Device', 'timeFrame': '6-8 months', 'description': 'Device deficiencies and Adverse Device Events and Serious Adverse Device Events regarding the Injection Device used during the MPC injection step.'}, {'measure': '1 hour pad test', 'timeFrame': '6-8 months', 'description': 'Reduction in weight of standardized 1 hour pad test; From visit 3 (injection) to end of study visit. The pad test will be performed at the clinic under supervision of a member of the study personnel.'}], 'primaryOutcomes': [{'measure': 'Change of SUI episode frequency', 'timeFrame': '8-9 months', 'description': 'Assessment in episode change measured using a bladder diary, from baseline to 6 months after injection.'}], 'secondaryOutcomes': [{'measure': 'Incidence of (S)AEs', 'timeFrame': '6-8 months', 'description': 'AEs related to obtaining biopsy, injection procedure and MPCs, including surgical injury, scars, urinary tract infection, inflammation, pelvic pain, prolonged urinary retention, voiding dysfunction, de novo urge incontinence, haematuria, aberrant tissue formation.\n\nMeasured from Visit 2 (biopsy) to End of Study.'}, {'measure': 'Number of patients with any clinical significant findings', 'timeFrame': '8-9 months', 'description': 'Number of patients with any clinically significant findings based on physical examination, standard haematology, clinical chemistry and urinalysis profiles, blood pressure (BP), pulse and adverse events recordings at baseline, 1 month, 3 months and 6 months post-implantation.'}, {'measure': 'Change in 24 hour pad weight', 'timeFrame': '8-9 months', 'description': 'Change in pad weight based on using regular pad tests, from baseline to 6 months after injection.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['SUI', 'Incontinence', 'rhabdomyosphincter', 'urine', 'Stress Incontinence', 'LUTS', 'lower urinary tract'], 'conditions': ['Female Stress Urinary Incontinence']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.muvon-trials.com', 'label': 'Website for Phase II Study'}]}, 'descriptionModule': {'briefSummary': 'The objective of the SUISSE MPC 2 study is to treat stress urinary incontinence in adult women.', 'detailedDescription': "Stress urinary incontinence (SUI) is the loss of small amounts of urine associated with coughing, laughing, sneezing, exercising or other activities that increase pressure on the abdomen and, subsequently, the bladder.\n\nThe goal of the SUISSE MPC2 study is to treat SUI in women using their own autologous muscle precursor cells. To generate enough outcome data, a sufficient number of patients will be enrolled to yield evaluable data from 30 patients.\n\nThe study will be conducted as a self-controlled case series (SCCS) with each patient serving as their own comparators. Patients will participate in the study for up to approximately 8 to 9 months, including a baseline visit for screening, a visit to obtain a muscle biopsy approximately 12 weeks later, an injection of MPCCOLs up to 5 weeks later, and follow-up visits at 1, 3 and 6 months post injection. The injection is performed with ultrasound guidance using an endocavity ultrasound probe mounted on an Injection Device specifically designed for the clinical trial.\n\nAll patients will be treated with one of two doses of MPCCOL, assigned according to the study's randomization method.\n\nHalf of the participating patients will receive the tissue engineered product (TEP) dose that was previously studied in the completed phase I study. The other half of the participants will receive a higher dose of the cell therapy to investigate the effects of dose increase. All study participants will be monitored via medical examinations.\n\nSeparate from the Principal Investigator, safety events will be reported to and investigated by an independent Data Safety Monitoring Board (DSMB) consisting of independent physicians and experts in the field. Data regarding the functionality and safety of the Injection Device will also be collected."}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'genderBased': True, 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Predominant clinical diagnosis of SUI\n* Stress incontinence ≥ grade I for at least 6 months\n* Patient has at least once been treated with, and failed prior conservative treatments\n* Patient had no improvement of SUI symptoms for at least 6 months before enrollment\n* Patients with a certain amount of leaks or /and a predefined pad weight at screening\n* Candidate for a surgical treatment\n* Negative blood test: Human immunodeficiency virus (HIV 1/2), Hepatitis B HBsAg, Anti HBc, Hepatitis C, Anti-HCV-Ab and Syphilis\n* Negative laboratory or blood test, and medical examination to eliminate risk of sexually transmitted diseases (STD) per investigators' discretion\n* Competent to comprehend, sign, and date informed consent form before any study-specific procedure is performed\n* Able to communicate well with the Investigator, and to understand and comply with the requirements of the study including answering the required questionnaires\n\nExclusion Criteria:\n\n* History of anti-incontinence surgery or prolapse surgery.\n* Prolapse\n* Diagnosed Hypermobile Urethra\n* Previous diagnosis of any of the following conditions, disorders, or diseases of the urinary tract:\n\n * Clinically significant cystocele or rectocele\n * Ureteric bladder, urethral or rectal fistula\n * Uncorrected congenital abnormality leading to urinary incontinence\n * Interstitial cystitis\n* Urinary urgency that results in leakage (as a predominant symptom)\n* Adult enuresis\n* Urodynamically proven detrusor instability or detrusor sphincter dyssynergia (DSD)\n* Sensory urgency defined as first sensation of bladder fill (urge to void) of \\<100 ml\n* No sensation at any time during the simple filling cystometry procedure\n* Known urethral Stenosis (ureterocystoscopy) or urethral diverticulum\n* History of cancer (\\< 5 year of remission) or history of pelvic radiotherapy\n* Immunosuppressed patients\n* Women who are pregnant or become pregnant during the course of the study, breast feeding or \\<12 months postpartum\n* Untreated symptomatic urinary tract infection\n* Fever (as defined by ≥ 38,5°C, axillar measurement), any infectious disease, cold or flu within the last 7 days\n* Unstable severe systemic disease including uncontrolled hypertension, unstable angina, or myocardial infarction, severe coagulation disorders, bleeding diathesis, emboli, thrombophlebitis, infectious diseases, poor wound healing, and poorly controlled diabetes mellitus within 6 months before enrolment\n* Known allergy/intolerance to at least one of the active ingredients or excipients of the investigational products\n* Known allergy/intolerance to Penicillin or Streptomycin.\n* Known genetically determined or acquired muscular disease, known neurological disorder (Parkinson's disease, multiple sclerosis, spina bifida, medullary traumatism, Creutzfeldt-Jakob disease).\n* Medication regimen including estrogens, anti-estrogens or diuretics where dose and/or frequency has not been stable for at least the past 12 weeks or is anticipated to change during the course of the study.\n* Chronic use of defined drugs and not stopped prior to inclusion into or including the study. Selective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI), alpha-receptor antagonists/agonists, beta-3-receptor agonists or anticholinergic/-muscarinic drugs.\n* Have any clinically significant coexisting condition or symptoms that, in the opinion of the investigator, would put the safety of the participant at risk.\n* Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results.\n* Medication known to affect lower urinary tract function.\n* Patients having any electrical device inside their body (such as a cochlear implant, TENS stimulator (for pain), vagal nerve stimulator, brain stimulator, gastric pacemaker, bladder stimulator, or an implanted mechanical pump (such an insulin pump or pain pump).\n* Patients having a cardiac pacemaker or defibrillator implant.\n* Patients with Starr-Edwards artificial heart valve.\n* Patients that suffer from claustrophobia."}, 'identificationModule': {'nctId': 'NCT05534269', 'acronym': 'SUISSE MPC2', 'briefTitle': "Stress Urinary Incontinence Study to Assess Safety and Efficacy of Muvon's Muscle Precursor Cell Therapy", 'organization': {'class': 'OTHER', 'fullName': 'University of Zurich'}, 'officialTitle': "Stress Urinary Incontinence Study to Assess Safety and Efficacy of Muvon's Muscle Precursor Cell Therapy", 'orgStudyIdInfo': {'id': 'SUISSE MPC2'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Low dose', 'description': 'Already human tested low dose from phase I study', 'interventionNames': ['Biological: autologous muscle precursor cells']}, {'type': 'EXPERIMENTAL', 'label': 'High dose', 'description': 'First in human dose used for efficacy reasons during phase II', 'interventionNames': ['Biological: autologous muscle precursor cells']}], 'interventions': [{'name': 'autologous muscle precursor cells', 'type': 'BIOLOGICAL', 'description': 'Patients own Muscle Precursor Cells are isolated and injected into the rhabdomyosphincter', 'armGroupLabels': ['High dose', 'Low dose']}]}, 'contactsLocationsModule': {'locations': [{'zip': '8091', 'city': 'Zurich', 'state': 'Canton of Zurich', 'country': 'Switzerland', 'facility': 'University Hospital Zurich', 'geoPoint': {'lat': 47.36667, 'lon': 8.55}}], 'overallOfficials': [{'name': 'Tobias Schmidli, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Zurich'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Zurich', 'class': 'OTHER'}, 'collaborators': [{'name': 'GCP-Service International Ltd. & Co. KG', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}